Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Treviso – page 27

920 clinical trials in Treviso, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Treviso at a glance
920
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

920 trials in Treviso

Open in trial search

Squamous cell carcinoma of head and neck

Recruiting

Study on the Effects of Ficlatuzumab and Cetuximab for Adults with Recurrent or Metastatic HPV-Negative Head and Neck Cancer

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Aveo Pharmaceuticals Inc.

Colorectal cancer metastatic

Recruiting

Study on Intermittent vs. Continuous Panitumumab and FOLFIRI for Patients with Unresectable Left-Sided Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Panitumumab
  • Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale

Non-small cell lung cancer

Recruiting

Study of NVL-520 for Patients with Advanced ROS1-Positive Lung Cancer and Other Solid Tumors

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Nuvalent Inc.

Peritoneal sarcoma+5

Recruiting

Study on Adjusting Chemotherapy with Carboplatin and Paclitaxel for Patients with Poor Prognostic Ovarian Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Arcagy Gineco

Chronic lymphocytic leukaemia+1

Recruiting

Study on Lisaftoclax and Acalabrutinib for Patients with Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:Ascentage Pharma Group Inc.

Ovarian cancer

Recruiting

Study Comparing Avutometinib and Defactinib with Other Treatments for Patients with Recurrent Low-Grade Serous Ovarian Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Verastem Inc.

Nephroblastoma

Recruiting

Study Comparing Vincristine, Actinomycin-D, and Doxorubicin with Vincristine, Carboplatin, and Etoposide for Stage IV Childhood Kidney Cancer Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Carboplatin
  • Sponsor:GPOH gGmbH

Aortic valve stenosis

Recruiting

Study on Pelacarsen for Slowing Calcific Aortic Valve Stenosis in Patients

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Pulmonary embolism

Recruiting

Study on the Effectiveness of Oxygen for Patients with Intermediate-Risk Acute Pulmonary Embolism

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Oxygen
  • Sponsor:Fundacion Para La Investigacion Biomedica Del Hospital Universitario Ramon Y Cajal

Chondrosarcoma

Recruiting

Study of ivosidenib in adults with advanced or metastatic chondrosarcoma with IDH1 mutation who are untreated or have had one prior treatment

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ivosidenib
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Non-small cell lung cancer

Recruiting

Study of MK-1084 and Pembrolizumab for First-Line Treatment in Patients with Metastatic Non-Small Cell Lung Cancer with KRAS G12C Mutation and High PD-L1 Levels

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:MK-1084
  • Sponsor:Merck Sharp & Dohme LLC

Factor VIII deficiency+3

Recruiting

Study on the Effectiveness of Concizumab for Children Under 12 with Hemophilia A or B, With or Without Inhibitors

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Concizumab
  • Sponsor:Novo Nordisk A/S

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Treviso

What the registry says about research in the country

01 Hematologic Oncology

Innovative trials exploring treatments for Acute Myeloid Leukemia and Lymphomas, including studies on targeted therapies combined with standard chemotherapy. Research focuses on improving treatment outcomes for various blood cancers.

  • Gemtuzumab Ozogamicin for AML
  • Daratumumab for Plasmablastic Lymphoma
  • Follicular Lymphoma Treatment Optimization

Advanced therapeutic approaches aim to enhance minimal residual disease control and patient outcomes.

02 Gynecologic Oncology

Comprehensive research into ovarian cancer treatments, including studies of maintenance therapies and novel drug combinations. Investigations focus on both recurrent and newly diagnosed cases.

  • Olaparib Maintenance Therapy
  • Low-grade Serous Carcinoma Treatment
  • Cervical Cancer Prevention

Studies emphasize personalized treatment approaches based on specific genetic markers and disease characteristics.

03 Respiratory Medicine

Groundbreaking research in lung cancer and severe respiratory conditions, including targeted therapies for specific genetic mutations and innovative treatment combinations.

  • ALK-positive NSCLC Treatment
  • Small Cell Lung Cancer Therapy
  • Severe Asthma Management

Focus on developing personalized treatment strategies for various lung cancer subtypes and respiratory conditions.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.